Synthesis of Combretastatin A-4 and 3'-Aminocombretastatin A-4 derivatives with Aminoacid Containing Pendants and Study of Their Interaction with Tubulin and as Downregulators of the VEGF, hTERT and c-Myc Gene Expression.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
04 Feb 2020
Historique:
received: 18 12 2019
revised: 29 01 2020
accepted: 01 02 2020
entrez: 9 2 2020
pubmed: 9 2 2020
medline: 18 11 2020
Statut: epublish

Résumé

Natural product combretastatin A-4 (CA-4) and its nitrogenated analogue 3'-aminocombretastatin A-4 (AmCA-4) have shown promising antitumor activities. In this study, a range of CA-4 and AmCA-4 derivatives containing amino acid pendants have been synthesized in order to compare their biological actions with those of their parent compounds. Thus, inhibition of cell proliferation on tumor cell lines HT-29, MCF-7 and A-549, as well as on the nontumor cell line HEK-273; in vitro tubulin polymerization; mitotic cell arrest; action on the microtubule cell network and inhibition of VEGF, hTERT, and c-Myc genes have been evaluated. Some AmCA-4 derivatives bearing L-amino acids exhibited inhibition of cell proliferation at low nanomolar levels exceeding the values shown by AmCA-4. Furthermore, while CA-4 and AmCA-4 derivatives do not show significant effects on the in vitro tubulin polymerization and cell cycle arrest, some selected CA-4 and AmCA-4 derivatives are able to cause total depolymerization of the microtubule network on A-549 cells. The best results were obtained in the inhibition of gene expression, particularly on the

Identifiants

pubmed: 32033084
pii: molecules25030660
doi: 10.3390/molecules25030660
pmc: PMC7037732
pii:
doi:

Substances chimiques

Antineoplastic Agents, Phytogenic 0
MYC protein, human 0
Proto-Oncogene Proteins c-myc 0
Stilbenes 0
Tubulin 0
VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0
TERT protein, human EC 2.7.7.49
Telomerase EC 2.7.7.49
fosbretabulin I5590ES2QZ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministerio de Economia y Competitividad
ID : CTQ2014-52949-P
Organisme : Ministerio de Ciencia, Innovación y Universidades
ID : RTI2018-097345-B-I00
Organisme : Jaume I University
ID : UJI-B2018-38

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

Adv Cancer Res. 2010;107:163-224
pubmed: 20399964
Signal Transduct Target Ther. 2018 Feb 23;3:5
pubmed: 29527331
J Med Chem. 2014 Dec 26;57(24):10391-403
pubmed: 25426924
J Nat Prod. 1987 Jan-Feb;50(1):119-31
pubmed: 3598594
Eur J Med Chem. 2013 Nov;69:863-71
pubmed: 24121309
Invest New Drugs. 1999;17(3):195-212
pubmed: 10665474
Bioorg Med Chem. 2006 May 1;14(9):3231-44
pubmed: 16442292
J Med Chem. 2006 Oct 19;49(21):6412-5
pubmed: 17034147
Br J Cancer. 2008 Feb 26;98(4):677-83
pubmed: 18231105
Anticancer Res. 2001 Sep-Oct;21(5):3457-60
pubmed: 11848509
Arch Pharm (Weinheim). 2015 Aug;348(8):541-7
pubmed: 26085125
J Med Chem. 1995 May 12;38(10):1666-72
pubmed: 7752190
Bioorg Med Chem. 2013 Dec 1;21(23):7267-74
pubmed: 24145138
Eur J Med Chem. 2018 Mar 10;147:183-193
pubmed: 29432949
Neoplasia. 2006 Sep;8(9):702-7
pubmed: 16984727
Sci Rep. 2016 Jun 24;6:28139
pubmed: 27338725
Semin Cancer Biol. 2011 Dec;21(6):349-53
pubmed: 22015685
Nat Med. 2011 Nov 07;17(11):1359-70
pubmed: 22064426
Vasc Health Risk Manag. 2006;2(3):213-9
pubmed: 17326328
J Pharmacol Exp Ther. 2015 Nov;355(2):212-27
pubmed: 26354991
Eur J Med Chem. 2019 Jan 15;162:781-792
pubmed: 30502686
Bioorg Med Chem. 2014 Oct 1;22(19):5155-67
pubmed: 25192811
Oncologist. 2011;16(6):844-58
pubmed: 21632459
J Med Chem. 1998 Jul 30;41(16):3022-32
pubmed: 9685242
Eur J Med Chem. 2014 Nov 24;87:125-30
pubmed: 25240870
Eur J Med Chem. 2017 Jan 27;126:526-535
pubmed: 27915168
Cell. 2012 Mar 30;149(1):22-35
pubmed: 22464321
Expert Opin Investig Drugs. 2009 Feb;18(2):189-97
pubmed: 19236265

Auteurs

Raül Agut (R)

Departamento de Química Inorgánica y Orgánica, Universidad Jaume I, E-12071 Castellón, Spain.

Eva Falomir (E)

Departamento de Química Inorgánica y Orgánica, Universidad Jaume I, E-12071 Castellón, Spain.

Juan Murga (J)

Departamento de Química Inorgánica y Orgánica, Universidad Jaume I, E-12071 Castellón, Spain.

Celia Martín-Beltrán (C)

Departamento de Química Inorgánica y Orgánica, Universidad Jaume I, E-12071 Castellón, Spain.

Raquel Gil-Edo (R)

Departamento de Química Inorgánica y Orgánica, Universidad Jaume I, E-12071 Castellón, Spain.

Alberto Pla (A)

Departamento de Química Inorgánica y Orgánica, Universidad Jaume I, E-12071 Castellón, Spain.

Miguel Carda (M)

Departamento de Química Inorgánica y Orgánica, Universidad Jaume I, E-12071 Castellón, Spain.

J Alberto Marco (JA)

Departamento de Química Orgánica, Universidad de Valencia, E-46100 Valencia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH